Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine

Takuya Tsuchihashi, Michio Ueno, Mitsuhiro Tominaga, Tomoko Kajioka, Uran Onaka, Kimika Eto, Kenichi Goto

研究成果: ジャーナルへの寄稿記事

22 引用 (Scopus)

抄録

The objective of the present study was to determine antiproteinuric effect of an N-type calcium channel blocker - cilnidipine. Subjects were 43 essential or renal hypertensive subjects who had been taking calcium channel blockers other than cilnidipine for at least 6 months. All patients had proteinuria greater than 0.2 g/day in spite of fair blood pressure control (< 150/90 mmHg). Calcium channel blockers in 25 patients (62 ± 3 years) were switched to cilnidipine (cilnidipine group), whereas other 18 patients (58 ± 3 years) continued to take originally prescribed calcium channel blockers (control group). The 24-hr urine collections were done at baseline and after 6 months of the follow-up period. Baseline characteristics including age, blood pressure levels, body mass index and creatinine clearance were similar between cilnidipine and control groups. Urinary protein excretion also was comparable between cilnidipine (0.61 ± 0.10 g/day) and control (0.86 ± 0.17 g/day) groups. Urinary protein significantly decreased after 6 months in cilnidipine group (-0.21 ± 0.11 g/day, -36%, p < 0.01), whereas it did not change in control group (+0.01 ± 0.15 g/day, 0.4%, ns). There were no significant changes in blood pressure, serum creatinine, creatinine clearance, estimated protein intake, and urinary salt excretion during the follow-up period in either group. The reduction of urinary protein by cilnidipine was evident in essential hypertensives (-54 ± 9%, n = 18, p < 0.01) but not in renal hypertensives (+10 ± 35%, n = 7, ns). Results suggest that cilnidipine has an antiproteinuric effect especially in patients with essential hypertension.

元の言語英語
ページ(範囲)583-591
ページ数9
ジャーナルClinical and Experimental Hypertension
27
発行部数8
DOI
出版物ステータス出版済み - 11 2005
外部発表Yes

Fingerprint

N-Type Calcium Channels
Calcium Channel Blockers
Creatinine
Blood Pressure
Control Groups
Proteins
Kidney
cilnidipine
Urine Specimen Collection
Proteinuria
Body Mass Index
Salts

All Science Journal Classification (ASJC) codes

  • Internal Medicine

これを引用

Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine. / Tsuchihashi, Takuya; Ueno, Michio; Tominaga, Mitsuhiro; Kajioka, Tomoko; Onaka, Uran; Eto, Kimika; Goto, Kenichi.

:: Clinical and Experimental Hypertension, 巻 27, 番号 8, 11.2005, p. 583-591.

研究成果: ジャーナルへの寄稿記事

Tsuchihashi, T, Ueno, M, Tominaga, M, Kajioka, T, Onaka, U, Eto, K & Goto, K 2005, 'Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine', Clinical and Experimental Hypertension, 巻. 27, 番号 8, pp. 583-591. https://doi.org/10.1080/10641960500298558
Tsuchihashi, Takuya ; Ueno, Michio ; Tominaga, Mitsuhiro ; Kajioka, Tomoko ; Onaka, Uran ; Eto, Kimika ; Goto, Kenichi. / Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine. :: Clinical and Experimental Hypertension. 2005 ; 巻 27, 番号 8. pp. 583-591.
@article{970313e421084612bbe1b9e734e05966,
title = "Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine",
abstract = "The objective of the present study was to determine antiproteinuric effect of an N-type calcium channel blocker - cilnidipine. Subjects were 43 essential or renal hypertensive subjects who had been taking calcium channel blockers other than cilnidipine for at least 6 months. All patients had proteinuria greater than 0.2 g/day in spite of fair blood pressure control (< 150/90 mmHg). Calcium channel blockers in 25 patients (62 ± 3 years) were switched to cilnidipine (cilnidipine group), whereas other 18 patients (58 ± 3 years) continued to take originally prescribed calcium channel blockers (control group). The 24-hr urine collections were done at baseline and after 6 months of the follow-up period. Baseline characteristics including age, blood pressure levels, body mass index and creatinine clearance were similar between cilnidipine and control groups. Urinary protein excretion also was comparable between cilnidipine (0.61 ± 0.10 g/day) and control (0.86 ± 0.17 g/day) groups. Urinary protein significantly decreased after 6 months in cilnidipine group (-0.21 ± 0.11 g/day, -36{\%}, p < 0.01), whereas it did not change in control group (+0.01 ± 0.15 g/day, 0.4{\%}, ns). There were no significant changes in blood pressure, serum creatinine, creatinine clearance, estimated protein intake, and urinary salt excretion during the follow-up period in either group. The reduction of urinary protein by cilnidipine was evident in essential hypertensives (-54 ± 9{\%}, n = 18, p < 0.01) but not in renal hypertensives (+10 ± 35{\%}, n = 7, ns). Results suggest that cilnidipine has an antiproteinuric effect especially in patients with essential hypertension.",
author = "Takuya Tsuchihashi and Michio Ueno and Mitsuhiro Tominaga and Tomoko Kajioka and Uran Onaka and Kimika Eto and Kenichi Goto",
year = "2005",
month = "11",
doi = "10.1080/10641960500298558",
language = "English",
volume = "27",
pages = "583--591",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Antiproteinuric effect of an N-type calcium channel blocker, cilnidipine

AU - Tsuchihashi, Takuya

AU - Ueno, Michio

AU - Tominaga, Mitsuhiro

AU - Kajioka, Tomoko

AU - Onaka, Uran

AU - Eto, Kimika

AU - Goto, Kenichi

PY - 2005/11

Y1 - 2005/11

N2 - The objective of the present study was to determine antiproteinuric effect of an N-type calcium channel blocker - cilnidipine. Subjects were 43 essential or renal hypertensive subjects who had been taking calcium channel blockers other than cilnidipine for at least 6 months. All patients had proteinuria greater than 0.2 g/day in spite of fair blood pressure control (< 150/90 mmHg). Calcium channel blockers in 25 patients (62 ± 3 years) were switched to cilnidipine (cilnidipine group), whereas other 18 patients (58 ± 3 years) continued to take originally prescribed calcium channel blockers (control group). The 24-hr urine collections were done at baseline and after 6 months of the follow-up period. Baseline characteristics including age, blood pressure levels, body mass index and creatinine clearance were similar between cilnidipine and control groups. Urinary protein excretion also was comparable between cilnidipine (0.61 ± 0.10 g/day) and control (0.86 ± 0.17 g/day) groups. Urinary protein significantly decreased after 6 months in cilnidipine group (-0.21 ± 0.11 g/day, -36%, p < 0.01), whereas it did not change in control group (+0.01 ± 0.15 g/day, 0.4%, ns). There were no significant changes in blood pressure, serum creatinine, creatinine clearance, estimated protein intake, and urinary salt excretion during the follow-up period in either group. The reduction of urinary protein by cilnidipine was evident in essential hypertensives (-54 ± 9%, n = 18, p < 0.01) but not in renal hypertensives (+10 ± 35%, n = 7, ns). Results suggest that cilnidipine has an antiproteinuric effect especially in patients with essential hypertension.

AB - The objective of the present study was to determine antiproteinuric effect of an N-type calcium channel blocker - cilnidipine. Subjects were 43 essential or renal hypertensive subjects who had been taking calcium channel blockers other than cilnidipine for at least 6 months. All patients had proteinuria greater than 0.2 g/day in spite of fair blood pressure control (< 150/90 mmHg). Calcium channel blockers in 25 patients (62 ± 3 years) were switched to cilnidipine (cilnidipine group), whereas other 18 patients (58 ± 3 years) continued to take originally prescribed calcium channel blockers (control group). The 24-hr urine collections were done at baseline and after 6 months of the follow-up period. Baseline characteristics including age, blood pressure levels, body mass index and creatinine clearance were similar between cilnidipine and control groups. Urinary protein excretion also was comparable between cilnidipine (0.61 ± 0.10 g/day) and control (0.86 ± 0.17 g/day) groups. Urinary protein significantly decreased after 6 months in cilnidipine group (-0.21 ± 0.11 g/day, -36%, p < 0.01), whereas it did not change in control group (+0.01 ± 0.15 g/day, 0.4%, ns). There were no significant changes in blood pressure, serum creatinine, creatinine clearance, estimated protein intake, and urinary salt excretion during the follow-up period in either group. The reduction of urinary protein by cilnidipine was evident in essential hypertensives (-54 ± 9%, n = 18, p < 0.01) but not in renal hypertensives (+10 ± 35%, n = 7, ns). Results suggest that cilnidipine has an antiproteinuric effect especially in patients with essential hypertension.

UR - http://www.scopus.com/inward/record.url?scp=28444476977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444476977&partnerID=8YFLogxK

U2 - 10.1080/10641960500298558

DO - 10.1080/10641960500298558

M3 - Article

C2 - 16303635

AN - SCOPUS:28444476977

VL - 27

SP - 583

EP - 591

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 8

ER -